“PATH and OneWorld Health (OWH) [on Friday] announced that OWH will become an affiliate of PATH, bringing its drug development expertise and experience in neglected infectious diseases to bear on PATH’s mission of improving global health through innovation,” according to a PATH press release. The press release adds, “By becoming a PATH affiliate, OneWorld Health will be able to scale and accelerate its successful drug development efforts, which include developing a semisynthetic version of artemisinin, a key component in treating malaria, to help provide an affordable, stable source of the drug, alleviate shortages, and meet global demand” (12/16).